Sugi Predict

Sugi Predict / Compounds / SCHEMBL1372065

SCHEMBL1372065

SCHEMBL1372065

COC(=O)[C@@H](NC(=O)OC(C)(C)C)C1CCCCC1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ AAK1 Q2M2I8 4/20 0.48
▸ GAA P10253 1/20 0.46
▸ EPHX1 P07099 2/20 0.44
▸ HDAC4 P56524 1/20 0.44
▸ HDAC1 Q13547 1/20 0.44
▸ HDAC6 Q9UBN7 1/20 0.44
▸ CA12 O43570 1/20 0.44
▸ CA14 Q9ULX7 1/20 0.44
▸ BTK Q06187 1/20 0.43
▸ CTSK P43235 3/20 0.43
▸ CTSS P25774 1/20 0.43
▸ CACNA1B Q00975 2/20 0.40
▸ THRB P10828 1/20 0.39
▸ CTSL P07711 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ NPR3 P17342 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1372066 1.00 AAK1 (0.48) AAK1GAAEPHX1HDAC4HDAC1
SCHEMBL21904477 1.00 AAK1 (0.48) AAK1GAAEPHX1HDAC4HDAC1
SCHEMBL24103813 0.98 AAK1 (0.49) AAK1GAAEPHX1HDAC4HDAC1
SCHEMBL29090746 0.98 AAK1 (0.49) AAK1GAAEPHX1HDAC4HDAC1
SCHEMBL30878159 0.98 AAK1 (0.49) AAK1GAAEPHX1HDAC4HDAC1
SCHEMBL15602067 0.95 BTK (0.48) AAK1GAAEPHX1HDAC4HDAC1
SCHEMBL16923503 0.95 BTK (0.48) AAK1GAAEPHX1HDAC4HDAC1
SCHEMBL14831257 0.92 AAK1 (0.47) AAK1CA12CA14BTKCTSK
SCHEMBL21201991 0.92 AAK1 (0.47) AAK1CA12CA14BTKCTSK
SCHEMBL14831258 0.92 AAK1 (0.47) AAK1CA12CA14BTKCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600728-B2 Interleukin-17 inhibitors NOVARTIS AG (CH) 2026-04-14 — — US disclosed
EP-4143195-B1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN PHARMACEUTICA NV (BE) 2025-05-21 — — EP disclosed
US-12024524-B2 Imidazopyridazines as modulators of IL-17 JANSSEN PHARMACEUTICA NV (BE) 2024-07-02 — — US disclosed
US-20230391782-A1 INTERLEUKIN-17 INHIBITORS NOVARTIS AG (CH) 2023-12-07 — — US disclosed
US-20230357254-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-11-09 — — US disclosed
US-20230357254-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-11-09 — — US disclosed
EP-4237417-A1 INTERLEUKIN-17 INHIBITORS Novartis AG (CH) 2023-09-06 — — EP disclosed
US-11702422-B2 Imidazopyridazines as modulators of IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-07-18 — — US disclosed
US-11702422-B2 Imidazopyridazines as modulators of IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-07-18 — — US disclosed
US-11702422-B2 Imidazopyridazines as modulators of IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-07-18 — — US disclosed
EP-1881001-A1 HCV NS-3 serine protease inhibitors Tibotec Pharmaceuticals Ltd. (IE) 2008-01-23 — — EP disclosed
EP-1881001-A1 HCV NS-3 serine protease inhibitors Tibotec Pharmaceuticals Ltd. (IE) 2008-01-23 — — EP disclosed
EP-1881002-A1 HCV NS-3 serine protease inhibitors Tibotec Pharmaceuticals Ltd. (IE) 2008-01-23 — — EP disclosed
US-20070203072-A1 Hcv Ns-3 Serine Protease Inhibitors MEDIVIR AB (SE) 2007-08-30 — — US disclosed
US-20070161574-A1 Hcv ns-3 serine protease inhibitors MEDIVIR AB (SE) 2007-07-12 — — US disclosed
EP-1713822-A2 HCV NS-3 SERINE PROTEASE INHIBITORS Medivir Aktiebolag (SE) 2006-10-25 — — EP disclosed
EP-1713823-A2 HCV NS-3 SERINE PROTEASE INHIBITORS Medivir Aktiebolag (SE) 2006-10-25 — — EP disclosed
WO-2005100334-A1 DIPEPTIDYL PEPTIDASE-IV INHIBITORS PFIZER PRODUCTS INC. (US) 2005-10-27 — — WO disclosed
WO-2005073195-A2 HCV NS-3 SERINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2005-08-11 — — WO disclosed
WO-2005073216-A2 HCV NS-3 SERINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2005-08-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230391782-A1 INTERLEUKIN-17 INHIBITORS IL17A, IL2, IL18 AAK1 1219/4885GAA 1406/4885EPHX1 1546/4885
US-20230357254-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 IL17A, IL23R, IL15 AAK1 2802/4885GAA 4186/4885EPHX1 2575/4885
US-12024524-B2 Imidazopyridazines as modulators of IL-17 IL17A, IL23R, IL15 AAK1 2802/4885GAA 4186/4885EPHX1 2575/4885
US-20070161574-A1 Hcv ns-3 serine protease inhibitors PRSS1, HPN, SPINT2 AAK1 2132/4885GAA 3103/4885EPHX1 1117/4885
US-20070203072-A1 Hcv Ns-3 Serine Protease Inhibitors HPN, CPN1, PRSS1 AAK1 2213/4885GAA 3201/4885EPHX1 2385/4885
US-11702422-B2 Imidazopyridazines as modulators of IL-17 IL17A, IL23R, IL15 AAK1 2802/4885GAA 4186/4885EPHX1 2575/4885
US-12600728-B2 Interleukin-17 inhibitors IL17A, IL2, IL1B AAK1 768/4885GAA 4682/4885EPHX1 4295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.